SpinX Technologies announces new, expanded advisory board
SpinX Technologies, a privately-held provider of technology to perform bioassays in research and in clinical settings, announced that it has expanded its Advisory Board with leading individuals from the Life Sciences business. The Advisory Board complements the strengths of SpinX Technologies' existing Board of Directors, and signals that SpinX Technologies has moved from microfluidics research to the market, specifically in the field of nanoliter scale liquid handling and assay detection for diagnostics and drug development. The new expanded Advisory Board shall ensure a smooth development of SpinX Technologies from a research-based company to a commercial sales and marketing operation:
- Andrew Carr holds a portfolio of Chairman and Non Executive Director positions with private equity funded life science companies including Akubio, deltaDOT, Teraview and SciBridge and has built substantial sales and marketing organizations globally for the life sciences, through his role as CEO of Amersham Pharmacia Biotech, both before and after the acquisition by GE of Amersham;
- Rajen Dalal, CEO of Aviir, brings his knowledge of the clinical diagnostics and blood banking sector through his experience as CEO of Chiron Blood Testing; in addition, at Guava Technologies he led an instrument company with products which have both research and clinical applications;
- André Marion, co-founder and previously CEO and Chairman of Applied Biosystems, Inc., has outstanding knowledge and experience of the manufacturing and servicing of complex instruments in the life sciences sector; in the early years at Applied Biosystems, André Marion was responsible for all aspects of operations.
SpinX Technologies boasts a Board of Directors composed of Sam Eletr (CEO, Population Genetics), Donald Fitzmaurice (Director, DFJ ePlanet Ventures), Mir Imran (Venture Partner and Senior Advisor, DFJ ePlanet), Thierry Jean (Chairman and CEO, Cerep), Seppo Mäkinen (Senior Partner, BioFund Management Oy Ltd), Philippe Peltier (Partner, Auriga Partners), Thomas Willis (VP for DNA Marketing, Affymetrix), Giuseppe Zocco (General Partner, Index Ventures), and Piero Zucchelli (Founder and CSO of SpinX Technologies).
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
